Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
about
Exploiting tumor epigenetics to improve oncolytic virotherapyTargeted therapies in sarcomas: challenging the challengeDeconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeuticsWhat Do We Know about the Role of miRNAs in Pediatric Sarcoma?Advances in sarcoma diagnostics and treatmentSynovial sarcoma: recent discoveries as a roadmap to new avenues for therapyHDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial SarcomaMelanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survivalSS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic ModifierEpigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma GroupPhase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomasEnhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulationGenome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cellsEpigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Molecular marks for epigenetic identification of developmental and cancer stem cellsPreclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaPoorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growthTargeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitroSynergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluationIdentification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay.Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis.A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.Newer medical therapies for metastatic soft tissue sarcoma.SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.Therapeutic applications of histone deacetylase inhibitors in sarcoma.
P2860
Q21131237-4F41A130-8821-477E-A3B1-649E1E3B8A8BQ21285014-4198DDA0-E811-46A5-9649-2C33A7BA3177Q24308344-810C1F89-B4B7-4385-835A-468F7599AA88Q26800124-1B190174-11CC-4FC2-9833-2E7A6CBFCC37Q28069695-4FB2B9A7-B5AF-432C-89C9-4AC0CA8E6695Q28087134-E151266C-67C3-45EC-A4BB-5C0722C2E699Q28468451-607D7436-2FAD-4DFC-BFCA-FF8280E3CC8FQ28483943-E9BE1C47-6E32-43F9-9718-C0DCF3B2DC55Q28550973-078A51F3-1389-42E3-926A-A894718A9FF7Q30914150-3246F65A-3B76-49B3-AD6B-C8DFC1A17802Q33409579-1516162A-E840-4C4E-B8F0-85F53A9D8009Q33419472-DBA4EB8D-1A00-4E1D-B67B-4E369393C8E3Q33425217-5EDFEBD3-4643-432D-80E9-531FC4A65A93Q33742171-1521DDF3-0DD0-4263-A724-089BD4639D6EQ33910609-DA731F7C-2C8F-47F8-931F-EC051FE5C0A3Q34200411-797E585D-870A-47CD-A0B8-F22BBF25CC98Q34272305-29C191F9-B808-4381-905C-A5740CA5F17EQ34621838-1AB30380-999E-4567-B9DC-D8B0A46D93EEQ34657445-1B6F6825-9A2D-4955-8348-BFFC0CB1968EQ35018901-2ADFE2DE-EB94-4D28-95D5-A0A9C62F8DB2Q35117949-7B8B7047-9C2C-465F-86F9-811936366BA9Q35734256-C26C4295-25DF-4F03-BF56-4056544047DDQ35789686-10F41A4F-7093-4A47-AB92-E5A509A8D1AFQ36001860-B1186FC1-79C6-43DC-9F4F-ADA97EBB8581Q36071514-41054194-D04A-4D5A-B434-313060B7D8B0Q36388149-5898DF0B-163C-4125-9E09-B2FA43A3B7E6Q36548712-889488C2-4A5E-43FE-9582-AA151F799A3FQ36850467-9074AF52-5087-4EEE-A957-7E2D93AEA0BBQ37138320-8DE427AA-8547-4BC3-A05F-3DFB09D09157Q37222595-C34DDB37-3E2B-4973-A70E-F71151BE64A7Q37376281-11863BBB-72D9-4D53-B48B-5810DCF20C8DQ37468623-5F04AD00-C6AB-43D6-B0BB-B25432AD5AEDQ37737327-3F628052-F4B6-4A80-9450-9467334DF5C8Q37962606-7589F17B-151F-41FB-B48A-DA2AFC30D6A6Q38336253-DFB089E3-8CFD-4794-BD1E-62108204A299Q38567366-B805DD05-6CDB-4EF3-B863-4948D0484D86Q38953852-8A7EE6AD-DE2E-46D0-A7D8-D4D548154AF4Q39012067-10426B6A-AEB4-462D-8CE0-83B0C17B9EE7Q39069350-9455FB40-F658-4305-B94B-0E5DA22A285AQ39450827-58B4EDC1-BC6F-4F4F-B6C0-152C4D0C65D3
P2860
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.
@en
type
label
Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.
@en
prefLabel
Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.
@en
P2093
P50
P1433
P1476
Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.
@en
P2093
Ad Geurts van Kessel
Anke H A van Dijk
Diederik R H de Bruijn
Joanna M Lubieniecka
Neal Poulin
Torsten O Nielsen
P304
P356
10.1158/0008-5472.CAN-08-0092
P407
P577
2008-06-01T00:00:00Z